Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy-Reference-Cited by-同舟云学术

Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy

Published:2009-07-24 Issue:1 Volume:257 Page:15-23
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Schepelmann Karsten,Winter Yaroslav,Spottke Annika E.,Claus Detlef,Grothe Christoph,Schröder Rolf,Heuss Dieter,Vielhaber Stefan,Mylius Veit,Kiefer Reinhard,Schrank Bertold,Oertel Wolfgang H.,Dodel Richard

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-009-5256-6.pdf

Reference42 articles.

1. Barber JA, Thompson SG (2000) Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 19:3219–3236

2. Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 124:96–107

3. Carpenter J, Bithell J (2000) Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 19:1141–1164

4. Christensen PB, Jensen TS, Tsiropoulos I, Sorensen T, Kjaer M, Hojer-Pedersen E, Rasmussen MJ, Lehfeldt E, de Fine Olivarius B (1993) Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology 43:1779–1783

5. Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, London

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scientific plurality and amyotrophic lateral sclerosis (ALS): A philosophical and historical perspective on Charcot’s texts;Journal of the History of the Neurosciences;2024-08-20

2. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti–acetylcholine receptor antibody–positive generalized myasthenia gravis;Journal of Managed Care & Specialty Pharmacy;2024-06

3. Nonpharmacological intervention therapies for dementia: potential break-even intervention price and savings for selected risk factors in the European healthcare system;BMC Public Health;2024-05-13

4. The impact of myasthenia gravis severity on work and daily activities;Muscle & Nerve;2024-02-13

5. Fitness and walking outcomes following aerobic and lower extremity strength training in facioscapulohumeral dystrophy: a case series;International Journal of Rehabilitation Research;2024-01-06